These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21723733)

  • 21. Histone deacetylases: structural determinants of inhibitor selectivity.
    Micelli C; Rastelli G
    Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors.
    Wang DF; Wiest O; Helquist P; Lan-Hargest HY; Wiech NL
    J Med Chem; 2004 Jun; 47(13):3409-17. PubMed ID: 15189037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.
    Lin X; Chen W; Qiu Z; Guo L; Zhu W; Li W; Wang Z; Zhang W; Zhang Z; Rong Y; Zhang M; Yu L; Zhong S; Zhao R; Wu X; Wong JC; Tang G
    J Med Chem; 2015 Mar; 58(6):2809-20. PubMed ID: 25734520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection.
    Wagner FF; Lundh M; Kaya T; McCarren P; Zhang YL; Chattopadhyay S; Gale JP; Galbo T; Fisher SL; Meier BC; Vetere A; Richardson S; Morgan NG; Christensen DP; Gilbert TJ; Hooker JM; Leroy M; Walpita D; Mandrup-Poulsen T; Wagner BK; Holson EB
    ACS Chem Biol; 2016 Feb; 11(2):363-74. PubMed ID: 26640968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological characterization of amidopropenyl hydroxamates as HDAC inhibitors.
    Thaler F; Varasi M; Colombo A; Boggio R; Munari D; Regalia N; Rozio MG; Reali V; Resconi AE; Mai A; Gagliardi S; Dondio G; Minucci S; Mercurio C
    ChemMedChem; 2010 Aug; 5(8):1359-72. PubMed ID: 20572281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclic tetrapeptides with -SS- bridging between amino acid side chains for potent histone deacetylases' inhibition.
    Arai T; Ashraful Hoque M; Nishino N; Kim HJ; Ito A; Yoshida M
    Amino Acids; 2013 Oct; 45(4):835-43. PubMed ID: 23754115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate.
    Yang PM; Lin JH; Huang WY; Lin YC; Yeh SH; Chen CC
    Biochem Biophys Res Commun; 2010 Jan; 391(3):1396-9. PubMed ID: 20026300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
    Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
    Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
    Park H; Kim S; Kim YE; Lim SJ
    ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
    Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A series of novel, potent, and selective histone deacetylase inhibitors.
    Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen schistosoma mansoni.
    Stolfa DA; Marek M; Lancelot J; Hauser AT; Walter A; Leproult E; Melesina J; Rumpf T; Wurtz JM; Cavarelli J; Sippl W; Pierce RJ; Romier C; Jung M
    J Mol Biol; 2014 Oct; 426(20):3442-53. PubMed ID: 24657767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
    Reddy DN; Ballante F; Chuang T; Pirolli A; Marrocco B; Marshall GR
    J Med Chem; 2016 Feb; 59(4):1613-33. PubMed ID: 26681404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
    Botta CB; Cabri W; Cini E; De Cesare L; Fattorusso C; Giannini G; Persico M; Petrella A; Rondinelli F; Rodriquez M; Russo A; Taddei M
    J Med Chem; 2011 Apr; 54(7):2165-82. PubMed ID: 21417297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
    Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
    J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Fang H; Xu W
    Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
    Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.